More time for blood culturing device compliance in US:
This article was originally published in Clinica
Executive Summary
The US FDA has extended the compliance date for the rule revoking the exemption from the requirement to obtain premarket clearance for blood culturing system devices. The new date is December 26th, 1996. For further information, contact: Lisa Rooney at the CDRH. Tel: +1 (301) 594 4765, ext 164.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.